Multicentre Validation of CanCertain (Multi VaC)
Research type
Research Study
Full title
An observational study to validate the Clyz CanCertain Assay to assess the chemosensitivity and chemoresistance properties of stage III and IV Lung Carcinoma biopsy samples using unique 3D culture techniques and monitor cellular responses once exposed to various Therapeutic agents. This will lead to personalized cancer care for lung cancer patients improving morbidity and mortality; and reducing costs of cancer care.
IRAS ID
257007
Contact name
Martin Ledson
Contact email
Sponsor organisation
Clyz Labs Limited
Duration of Study in the UK
0 years, 8 months, 31 days
Research summary
Currently, lung cancer remains the most common cause of cancer death in the UK and accounts for 22% of all cancer deaths. It is the 2nd most common cancer in the UK and only 5% patients survive their disease for 10 years or more and just a third (32%) survive their disease for one year or more (Cancer Research UK Statistics).
Chemotherapy resistance in lung cancer is still a major hurdle for oncologists. Due to the small numbers of patient surviving their first year of disease, it is imperative that the correct treatment is started as soon as a diagnosis has been made.
The proposed study is to develop a universal Personalised treatment assay to benefit all lung cancer patients due to undergo chemotherapy. By collecting an additional sample from patient’s scheduled diagnostic biopsy, the tumour cells and circulating tumour cells from patient blood will be processed in the laboratory facility at Clyz Labs Limited using Clyz CanCertainTM assay, a 3D scaffold allowing for 3D cell culture to closely mimic the environment in which the tumour currently sits in within the body, and subject these in vitro cells to a panel of Therapeutic drugs.
The study is observational and will not influence the patient’s treatment course, however the information gathered will be invaluable for future research and development of Precision Medicine for Lung Cancer. We will collect tumour tissue and a small blood sample from consented patients with clinically diagnosed with stage III or IV Lung Carcinoma, who have been scheduled for a lung biopsy (CT Guided Biopsy or EBUS Guided Needle Aspiration or Bronchoscopic Biopsy) for diagnostic histology and are due to have palliative or curative chemotherapy.REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
18/NW/0842
Date of REC Opinion
7 Dec 2018
REC opinion
Favourable Opinion